LQDA Projected Dividend Yield

Liquidia Corp ( NASDAQ : LQDA )

Liquidia is a biopharmaceutical company focused on the development, manufacturing and commercialization of products with focus directed towards the treatment of pulmonary hypertension (PH). Co. conducts research and manufacturing of products by applying its proprietary PRINT® technology, a particle engineering platform. Co.'s products and candidates for PH include: YUTREPIATM (treprostinil) Inhalation Powder to Treat PAH, which is an inhaled dry powder formulation of treprostinil; and Treprostinil Injection, a Generic Version of Remodulin®, which contains the same active ingredient, same strength, same dosage forms and same inactive ingredient amounts as Remodulin®.

20 YEAR PERFORMANCE RESULTS